use
antimicrobi
agent
reduc
mortal
infecti
diseas
howev
excess
antibiot
use
caus
develop
antimicrobi
resist
amr
bacteria
infect
antimicrobi
resist
organ
becom
major
public
health
concern
due
difficulti
treat
result
increas
hospit
stay
cost
mortal
antimicrobi
resist
organ
increas
rapidli
new
drug
combat
pathogen
develop
antimicrobi
stewardship
program
asp
one
import
strategi
prevent
amr
addit
asp
improv
clinic
outcom
patient
reduc
advers
drug
reaction
proven
advantag
asp
necess
program
realiz
hospit
regardless
bed
size
teach
statu
import
role
infecti
diseas
specialist
id
implement
success
asp
proven
previou
studi
howev
studi
evalu
role
id
effect
asp
larg
academ
hospit
hand
studi
report
success
implement
asp
nonacadem
commun
nac
hospit
nac
hospit
would
need
modifi
strategi
implement
asp
fewer
resourc
alloc
larg
teach
hospit
korea
nac
hospit
challeng
implement
asp
facil
leadership
support
avail
idss
work
larg
academ
hospit
rare
hire
nac
hospit
sinc
middl
east
respiratori
syndromecoronaviru
outbreak
korean
govern
encourag
hospit
employ
infect
control
doctor
polici
consequ
korean
nation
health
insur
servic
reimburs
infect
control
cost
condit
doctor
nurs
alloc
infect
control
hospit
bed
accordingli
recent
increas
number
idss
work
infect
control
doctor
nac
hospit
idss
expect
play
major
role
asp
howev
yet
fulli
evalu
hypothes
id
could
potenti
solut
implement
success
asp
resourcelimit
set
aim
studi
therefor
evalu
impact
idsl
asp
chang
amount
antibiot
use
rate
multidrugresist
organ
mdro
acquisit
resourcelimit
nac
hospit
korea
conduct
retrospect
studi
kimpo
woori
hospit
nac
hospit
bed
korea
patient
admit
hospit
june
august
elig
particip
includ
patient
posit
cultur
methicillinresist
staphylococcu
aureu
mrsa
multidrugresist
acinetobact
baumannii
mdrab
multidrugresist
pseudomona
aeruginosa
mdrpa
type
specimen
receiv
least
h
admiss
multidrugresist
defin
resist
least
one
antibiot
carbapenem
aminoglycosid
fluoroquinolon
data
patient
includ
statist
analysi
organ
collect
data
clinic
characterist
electron
medic
record
patient
underli
comorbid
defin
use
intern
classif
diseas
revis
microorgan
identifi
use
autom
bacteri
identif
system
biomerieux
marcyi
etoil
franc
antimicrobi
suscept
test
interpret
use
clinic
laboratori
standard
institut
guidelin
studi
approv
institut
review
board
yonsei
univers
health
system
clinic
trial
center
approv
number
protocol
adher
tenet
declar
helsinki
sinc
studi
retrospect
natur
studi
particip
anonym
institut
review
board
waiv
requir
written
consent
patient
collect
data
monthli
antibiot
prescript
evalu
trend
amount
antibiot
use
studi
includ
parenter
antibiot
exclud
oral
topic
agent
classif
defin
daili
dose
ddd
antibiot
determin
accord
world
health
organ
anatom
therapeut
chemic
classif
group
antibiot
follow
aminoglycosid
gener
cephalosporin
carbapenem
glycopeptid
fluoroquinolon
penicillin
antibiot
includ
linezolid
colistin
tigecyclin
march
hospit
implement
initi
asp
led
intern
medicin
physician
without
infecti
diseas
train
associ
polic
defin
bylaw
introduc
throughout
hospit
polici
mainli
aim
limit
inappropri
use
prophylact
antibiot
surgeri
restrict
prescript
gener
cephalosporin
aminoglycosid
surgeri
addit
computer
prescript
monitor
produc
popup
alarm
physician
continu
prescrib
antibiot
design
restrict
linezolid
colistin
tigecyclin
glycopeptid
carbapenem
day
popup
alarm
system
restrict
monitor
prescript
antibiot
design
restrict
hospit
hire
id
first
time
march
three
month
later
id
began
lead
asp
asp
enforc
reduc
mdro
amount
antibiot
use
hospit
begin
june
id
intend
reduc
use
inappropri
antibiot
combin
overlap
antimicrobi
coverag
well
inappropri
use
prophylact
antibiot
surgeri
furthermor
endeavor
increas
appropri
use
carbapenem
glycopeptid
antipseudomon
cephalosporin
ceftazidim
cefepim
antibiot
linezolid
colistin
tigecyclin
physician
requir
consult
id
prescript
antibiot
design
restrict
id
assess
appropri
use
antibiot
recommend
proper
dosag
interv
optim
durat
treatment
consult
physician
also
check
result
cultur
studi
day
approv
antibiot
use
made
decis
whether
continu
prescript
chang
pattern
antibiot
consumpt
mdro
acquisit
accord
idsl
asp
june
august
analyz
use
interrupt
time
seri
implement
intervent
june
set
transit
period
three
month
allow
intervent
process
stabil
studi
divid
time
seri
two
segment
pre
postintervent
use
segment
regress
analysi
assess
longitudin
effect
idsl
asp
paramet
use
segment
regress
analysi
defin
follow
level
consid
valu
measur
begin
time
segment
trend
consid
rate
chang
measur
given
time
interv
level
chang
intervent
consid
averag
valu
chang
intervent
reflect
immedi
effect
intervent
trend
chang
intervent
consid
chang
slope
period
intervent
constitut
gradual
chang
segment
statist
use
test
presenc
autocorrel
verifi
seriou
autocorrel
compar
clinic
characterist
patient
mdro
acquisit
one
year
intervent
use
either
independ
ttest
chisquar
test
statist
analys
perform
use
sa
version
sa
institut
inc
cari
nc
usa
r
softwar
version
statist
signific
consid
p
june
august
preval
organ
report
clinic
specimen
mrsa
n
follow
mdrab
n
mdrpa
n
tabl
clinic
characterist
patient
hospitalacquir
mrsa
mdrpa
acquisit
differ
statist
intervent
among
patient
mdrab
acquisit
proport
solid
cancer
cardiovascular
diseas
higher
postintervent
period
preintervent
total
antibiot
use
chang
patientday
pd
pd
studi
period
tabl
follow
intervent
amount
antibiot
use
decreas
except
gener
cephalosporin
increas
pd
pd
demonstr
antibiot
consumpt
pattern
june
august
figur
accord
segment
regress
analysi
decreas
trend
amount
aminoglycosid
quinolon
consumpt
intervent
p
antibiot
tabl
follow
intervent
decreas
level
trend
total
amount
antibiot
consum
statist
signific
howev
intervent
promin
effect
use
antibiot
design
restrict
transit
period
among
antibiot
design
restrict
immedi
reduct
use
carbapenem
coeffici
p
glycopeptid
coeffici
p
antibiot
coeffici
p
although
signific
immedi
chang
observ
amount
gener
cephalosporin
use
includ
ceftazidimecefepim
signific
decreas
trend
follow
intervent
compar
preintervent
coeffici
p
addit
immedi
respons
use
carbapenem
show
signific
decreas
trend
intervent
coeffici
p
penicillin
subject
restrict
use
decreas
immedi
intervent
follow
immedi
reduct
transit
period
signific
chang
trend
use
glycopeptid
penicillin
antibiot
june
may
period
intervent
incid
mdro
acquisit
pd
mrsa
mdrab
mdrpa
respect
tabl
incid
mrsa
mdrab
acquisit
decreas
follow
intervent
pd
mrsa
pd
mdrab
howev
period
increas
incid
mdrpa
acquisit
pd
incid
mdro
acquisit
patient
admit
hospit
studi
period
present
figur
segment
regress
analysi
signific
increas
trend
observ
incid
mrsa
acquisit
intervent
coeffici
p
tabl
immedi
follow
transit
period
estim
incid
mrsa
acquisit
decreas
coeffici
p
signific
chang
trend
incid
mdrab
mdrpa
intervent
incid
mdrab
acquisit
drop
transit
period
coeffici
p
howev
mdrpa
acquisit
increas
coeffici
p
signific
trend
chang
incid
acquisit
mdro
intervent
demonstr
impact
id
implement
asp
resourcelimit
nac
hospit
korea
intervent
immedi
effect
reduct
antibiot
design
restrict
moreov
continu
decreas
trend
use
antibiot
intervent
addit
along
decreas
amount
antibiot
use
incid
mrsa
mdrab
acquisit
decreas
immedi
follow
idsl
asp
without
signific
trend
chang
immedi
effect
data
antibiot
use
nac
hospit
limit
korea
previous
report
amount
antibiot
use
larg
universityaffili
hospit
compar
rate
major
teach
hospit
current
studi
demonstr
similar
usag
rate
antibiot
nac
hospit
studi
also
report
hospit
size
import
predict
amount
antibiot
use
given
find
regardless
bed
size
medic
school
affili
hospit
requir
implement
asp
howev
major
korean
nac
hospit
still
program
insuffici
human
financi
inform
technolog
resourc
compar
larg
academ
medic
center
exampl
pharmacist
involv
asp
howev
korean
nac
hospit
staff
member
drug
expertis
one
core
element
success
hospit
asp
addit
although
nac
hospit
implement
asp
barrier
success
program
first
larg
proport
patient
nac
hospit
come
longterm
care
facil
therefor
like
suffer
recurr
aspir
pneumonia
sever
decubitu
ulcer
result
increas
chanc
antibiot
use
second
compar
larg
academ
hospit
reduc
antibiot
use
especi
wellreimburs
drug
may
financi
benefici
nac
hospit
therefor
asp
may
receiv
suffici
support
hospit
leadership
id
could
potenti
solut
implement
success
asp
disadvantag
nac
hospit
id
consult
reduc
antibiot
use
discontinu
inappropri
antibiot
increas
appropri
antibiot
use
chang
narrow
spectrum
antibiot
addit
involv
id
clinic
practic
associ
improv
patient
outcom
skill
set
id
engend
trust
physician
make
recept
id
suggest
appropri
antibiot
use
studi
use
gener
cephalosporin
tend
increas
intervent
coeffici
p
although
result
statist
signific
may
caus
chang
made
id
empir
antibiot
improperli
use
appropri
antibiot
similar
studi
conduct
small
nac
hospit
fewer
bed
studi
asp
also
proven
reduc
antibiot
use
lower
medic
cost
improv
antibiot
suscept
specif
pathogen
even
though
idss
spent
much
less
time
asp
studi
demonstr
success
result
implement
asp
howev
key
differ
exist
studi
compar
studi
first
hospit
pharmacist
dedic
asp
facilit
intervent
pharmacist
member
asp
team
lack
avail
pharmacist
korean
nac
hospit
second
take
less
time
develop
maintain
asp
smaller
hospit
stenehjem
et
al
report
averag
time
spent
asp
hour
per
week
hospit
bed
contrast
studi
id
requir
work
full
time
hospit
bed
dedic
time
asp
activ
addit
low
volum
patient
staff
member
mean
idsl
asp
well
establish
smaller
nac
hospit
expect
rapid
effect
better
complianc
larger
nac
hospit
therefor
think
studi
conduct
moderates
resourcelimit
nac
hospit
worthwhil
multipl
factor
associ
develop
amr
sever
studi
shown
strong
evid
suggest
effect
asp
reduc
preval
amr
well
antibiot
use
studi
also
show
idsl
asp
effect
reduct
amr
evalu
incid
mrsa
mdrab
mdrpa
acquisit
indic
amr
korea
pathogen
isol
frequent
clinic
specimen
also
caus
relev
infect
clinic
practic
staphylococcu
aureu
methicillin
resist
carbapenem
resist
acinetobact
baumannii
pseudomona
aeruginosa
respect
howev
unabl
evalu
incid
carbapenemresist
enterobacteriacea
cre
case
hospitalacquir
cre
facil
studi
cre
case
confirm
specimen
collect
prior
h
admiss
limit
studi
infect
control
program
could
confound
factor
decreas
incid
mdro
acquisit
howev
factor
unlik
affect
result
id
spent
time
meet
infect
control
exist
well
hospit
implement
infect
control
activ
signific
chang
method
infect
control
program
exampl
main
strategi
hand
hygien
educ
monitor
feedback
studi
period
perform
rate
maintain
anoth
limit
immedi
increas
incid
mdrpa
acquisit
despit
signific
decreas
carbapenem
use
previou
studi
show
reduc
carbapenem
use
associ
decreas
carbapenem
resist
pseudomona
aeruginosa
although
observ
result
howev
although
statist
signific
incid
mdrpa
acquisit
decreas
slope
follow
intervent
asp
effect
strategi
prevent
slow
develop
mdro
howev
difficult
nac
hospit
implement
success
asp
due
lack
multidisciplinari
resourc
shown
id
could
potenti
solut
success
implement
asp
resourcelimit
set
find
howev
verifi
differ
set
smaller
institut
thu
facilit
need
studi
